Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Beasley

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
The American Journal of Psychiatry|April 1, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trialG D Tollefson, C M Beasley, P V Tran, et al.
The American Journal of Psychiatry|August 18, 1999
Changes in weight during a 1-year trial of fluoxetineD Michelson, J D Amsterdam, F M Quitkin, et al.
The American Journal of Psychiatry|September 12, 1998
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatmentF W Reimherr, J D Amsterdam, F M Quitkin, et al.
International Journal of Psychiatry in Medicine|January 1, 1997
Fluoxetine in depressed patients on dialysisM Blumenfield, N B Levy, B Spinowitz, et al.
The Journal of Clinical Psychiatry|July 13, 1999
Changes in adverse events reported by patients during 6 months of fluoxetine therapyJ Zajecka, J D Amsterdam, F M Quitkin, et al.
The Journal of Clinical Psychiatry|August 11, 2000
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depressionP J McGrath, J W Stewart, E Petkova, et al.
BMJ (Clinical Research Ed.)|October 1, 1991
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depressionC M Beasley, B E Dornseif, J C Bosomworth, et al.
International Journal of Geriatric Psychiatry|December 19, 2001
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical dataJ S Kennedy, F P Bymaster, L Schuh, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
The American Journal of Psychiatry|April 1, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trialG D Tollefson, C M Beasley, P V Tran, et al.
The American Journal of Psychiatry|August 18, 1999
Changes in weight during a 1-year trial of fluoxetineD Michelson, J D Amsterdam, F M Quitkin, et al.
The American Journal of Psychiatry|September 12, 1998
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatmentF W Reimherr, J D Amsterdam, F M Quitkin, et al.
International Journal of Psychiatry in Medicine|January 1, 1997
Fluoxetine in depressed patients on dialysisM Blumenfield, N B Levy, B Spinowitz, et al.
The Journal of Clinical Psychiatry|July 13, 1999
Changes in adverse events reported by patients during 6 months of fluoxetine therapyJ Zajecka, J D Amsterdam, F M Quitkin, et al.
The Journal of Clinical Psychiatry|August 11, 2000
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depressionP J McGrath, J W Stewart, E Petkova, et al.
BMJ (Clinical Research Ed.)|October 1, 1991
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depressionC M Beasley, B E Dornseif, J C Bosomworth, et al.
International Journal of Geriatric Psychiatry|December 19, 2001
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical dataJ S Kennedy, F P Bymaster, L Schuh, et al.
Pageof 6